GSK plc (LSE:GSK) has not released major company-specific results in the past two weeks, so its second-quarter 2026 results remain the latest detailed update. In that announcement the pharmaceutical group said it had delivered a solid core results performance and continued momentum.
What happened
GSK published its second-quarter 2026 results in late July. The company headlined the release by saying it had delivered a solid Q2 core results performance and continued momentum.
GSK has also declared an interim dividend. The company pays dividends on a quarterly basis, so each declaration gives shareholders an update on the board's view of cash generation and its commitment to returns.
The second-quarter update followed GSK's full-year 2025 results earlier in 2026. At the time, GSK was optimistic for 2026 after fourth-quarter results beat forecasts. The 2025 performance was solid, but the outlook for 2026 was characterised as cautious.
Why it matters for investors
GSK plc is a constituent of the FTSE All-Share index in the Pharmaceuticals and Biotechnology sector. It is one of the UK's largest companies and focuses on vaccines, specialty medicines and general medicines.
Core results are the measure GSK uses to show underlying performance, excluding items such as amortisation of intangible assets, restructuring costs and certain legal charges. Solid core growth suggests demand for its key products and pipeline launches is holding up.
Momentum matters because large pharmaceutical companies must continually replace revenue from older drugs that lose patent protection. Investors judge GSK partly on whether new medicines, particularly in areas such as oncology, respiratory and HIV, can drive growth as older products face competition.
The contrast between the optimism reported after the fourth-quarter beat and the more cautious framing of the 2026 outlook highlights how investors weigh short-term delivery against longer-term questions, including patent expiries later in the decade and US drug pricing policy.
How the shares have performed
Shares in large pharmaceutical groups can be influenced by clinical trial results, regulatory decisions, litigation and political developments, particularly in the United States, which is the most important market for many drug makers.
What to watch next
The next scheduled milestone is GSK's third-quarter 2026 results, which on the company's usual quarterly timetable would be expected later this autumn. Investors will look for confirmation that the momentum described in the second quarter has continued and for any change to full-year guidance.
Investors will also look at core operating margins and earnings per share, as well as cash flow, which supports both the dividend and investment in R&D. Pipeline developments will be closely watched, including trial readouts and regulatory approvals for new medicines and vaccines. Updates on vaccine sales and specialty medicines will also be important indicators of growth.
The US policy environment, including drug pricing and trade measures affecting pharmaceuticals, remains a significant factor for the sector. Until the third-quarter results, the second-quarter update remains the most recent detailed view of GSK's performance.





_11_18_2026_09_42_19_750506.jpg)
Please wait processing your request...